BC2027 is a first-in-class ADC targeting GPC3 that, as of April 2024, received FDA clearance for in-human studies in GPC3-positive cancers after demonstrating in preclinical studies greater than 90% inhibition of tumor growth in some well-established GPC3-positive cancers [107] (Table 2). This evidence concerns the gene GPC3 and cancer.